Avalo Therapeutics, Inc. (NASDAQ:AVTX – Get Free Report) was the recipient of a large growth in short interest in December. As of December 15th, there was short interest totalling 12,640,000 shares, a growth of 23.8% from the November 30th total of 10,210,000 shares. Based on an average trading volume of 51,393,300 shares, the short-interest ratio […]
Avalo Therapeutics (NASDAQ:AVTX – Get Free Report) will be announcing its earnings results on Wednesday, August 2nd. Avalo Therapeutics (NASDAQ:AVTX – Get Free Report) last released its earnings results on Thursday, May 4th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.12. The firm had […]
Avalo Therapeutics (NASDAQ:AVTX – Get Free Report) is scheduled to be releasing its earnings data on Wednesday, August 2nd. Avalo Therapeutics (NASDAQ:AVTX – Get Free Report) last posted its earnings results on Thursday, May 4th. The company reported ($0.85) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.12. The business […]
Avalo Therapeutics, Inc. (NASDAQ:AVTX – Get Free Report) was the recipient of a large growth in short interest in the month of July. As of July 15th, there was short interest totalling 887,000 shares, a growth of 41.2% from the June 30th total of 628,400 shares. Currently, 7.4% of the shares of the stock are […]
Avalo Therapeutics, Inc. (NASDAQ:AVTX – Get Rating) major shareholder Caissa Capital Management Ltd. acquired 3,000 shares of the firm’s stock in a transaction that occurred on Friday, June 16th. The stock was purchased at an average cost of $3.90 per share, for a total transaction of $11,700.00. Following the completion of the purchase, the insider […]